ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

Post author:admERY
Post published:July 20, 2015
Post category:Newsroom

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

You Might Also Like

ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting

ERYTECH Pharma to present promising results for the treatment of Sickle Cell Disease

ERYTECH to Present at JMP Securities Life Science Conference